Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
17.53
-0.04 (-0.23%)
At close: Feb 9, 2026, 4:00 PM EST
17.18
-0.35 (-2.00%)
After-hours: Feb 9, 2026, 5:56 PM EST
Keros Therapeutics Employees
Keros Therapeutics had 82 employees as of September 30, 2025. The number of employees decreased by 78 or -48.75% compared to the same quarter last year.
Employees
82
Change
-78
Growth
-48.75%
Revenue / Employee
$3,008,756
Profits / Employee
$785,963
Market Cap
534.07M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 82 | -78 | -48.75% |
| Jun 30, 2025 | 148 | -1 | -0.67% |
| Mar 31, 2025 | 163 | 22 | 15.60% |
| Dec 31, 2024 | 169 | 33 | 24.26% |
| Sep 30, 2024 | 160 | 31 | 24.03% |
| Jun 30, 2024 | 149 | 28 | 23.14% |
| Mar 31, 2024 | 141 | 34 | 31.78% |
| Dec 31, 2023 | 136 | 31 | 29.52% |
| Sep 30, 2023 | 129 | 25 | 24.04% |
| Jun 30, 2023 | 121 | 24 | 24.74% |
| Mar 31, 2023 | 107 | 32 | 42.67% |
| Dec 31, 2022 | 105 | 45 | 75.00% |
| Sep 30, 2022 | 104 | 59 | 131.11% |
| Jun 30, 2022 | 97 | 53 | 120.45% |
| Mar 31, 2022 | 75 | 37 | 97.37% |
| Dec 31, 2021 | 60 | 25 | 71.43% |
| Sep 30, 2021 | 45 | 13 | 40.63% |
| Jun 30, 2021 | 44 | 16 | 57.14% |
| Mar 31, 2021 | 38 | 12 | 46.15% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| REGENXBIO | 353 |
| Vor Biopharma | 154 |
| Gossamer Bio | 145 |
| Lexicon Pharmaceuticals | 103 |
| Solid Biosciences | 100 |
| Verastem | 78 |
| Lexeo Therapeutics | 61 |
| Forte Biosciences | 16 |
KROS News
- 2 months ago - Keros Therapeutics Announces Final Results of Tender Offer - GlobeNewsWire
- 2 months ago - Keros Therapeutics Announces Preliminary Results of Tender Offer - GlobeNewsWire
- 3 months ago - Keros Therapeutics Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 4 months ago - Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares - GlobeNewsWire
- 4 months ago - Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital - GlobeNewsWire
- 5 months ago - Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting - GlobeNewsWire
- 5 months ago - Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences - GlobeNewsWire
- 6 months ago - ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment - PRNewsWire